Abstracts/Presentation Description
Jon Emery1
1University of Melbourne
Polygenic risk scores (PRS) have been validated for several common cancers including melanoma, breast, colorectal and prostate. The challenge now is how to apply these to clinical care, specifically to tailor cancer prevention and screening. In this presentation I will summarise evidence on risk-stratified cancer screening and the potential application of PRS for this purpose. I will present findings from our research on applying a PRS to tailor colorectal cancer screening and more recent data on using a multi-cancer PRS to provide tailored advice on screening for melanoma, breast, colorectal and prostate. This will include evidence on the psychosocial consequences of receiving a PRS and impacts on risk-appropriate cancer screening.
1University of Melbourne
Polygenic risk scores (PRS) have been validated for several common cancers including melanoma, breast, colorectal and prostate. The challenge now is how to apply these to clinical care, specifically to tailor cancer prevention and screening. In this presentation I will summarise evidence on risk-stratified cancer screening and the potential application of PRS for this purpose. I will present findings from our research on applying a PRS to tailor colorectal cancer screening and more recent data on using a multi-cancer PRS to provide tailored advice on screening for melanoma, breast, colorectal and prostate. This will include evidence on the psychosocial consequences of receiving a PRS and impacts on risk-appropriate cancer screening.
Speaker/Presenting Authors
Authors
Submitting/Presenting Authors
Prof Jon Emery - University of Melbourne (Vic, Australia)